Madrona Ventures has acquired the Obesity treatment’s European patent and the pending American patent application. Reportedly, the company will be starting the phase II double-blind placebo-controlled clinical trial
Acceleron Pharma has reported the preliminary results from the ACE-031 phase 1 single dose clinical trial indicating that ACE-031 was safe and well-tolerated at all dose levels and
Accumetrics has signed a new exclusive agreement with Grifols for the distribution of its VerifyNow in Spain, Portugal and Chile. The VerifyNow assesses response to life-saving antiplatelet therapies,
Ranbaxy Pharmaceuticals (RPI), a wholly owned subsidiary of Ranbaxy has entered into an agreement with Validus Pharmaceuticals (Validus) to market and distribute an authorized generic version of Rocaltrol
Meda has received FDA approval for Astepro (azelastine) nasal spray 0.15%, for the treatment of the symptoms of seasonal and perennial allergic rhinitis. The new Astepro nasal spray
Molecular Insight has entered into an agreement to sub-license its Onalta brand 90-Y edotreotide radiotherapeutic in certain countries in Europe, the Middle East, North Africa, Russia and Turkey
Nitec Pharma (Nitec) has reported positive results from the second pivotal phase III trial for its lead product, Lodotra for the treatment of rheumatoid arthritis (RA). The CAPRA-2
Sinovac Biotech has signed an agreement with Boryung Pharmaceutical to collaborate on marketing efforts and possible vaccine supply efforts to the government of South Korea for Sinovac’s H1N1
Santhera has initiated the pivotal phase III study with Catena/Sovrima for the treatment of Duchenne Muscular Dystrophy. Reportedly, the 12-month study will enroll up to 240 patients in
The Medicines Company has reported that the US Patent and Trademark Office (PTO) issued a new US patent No 7582727 (‘727 patent). The ‘727 patent relates to a
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.